Summary

Results of the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial [SHIFT; ISRCTN70429960] indicate that when added to standard therapy, ivabradine reduced heart rate and improved outcomes in subjects with systolic heart rate as early as 3 months [Swedberg K et al. Lancet 2010].